These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24136820)

  • 1. Drug discovery alliances in India--indications, targets, and new chemical entities.
    Differding E
    ChemMedChem; 2014 Jan; 9(1):43-60. PubMed ID: 24136820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
    Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
    Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indian pharma enters the global arena.
    Singh S
    Cell; 2007 Mar; 128(5):811-4. PubMed ID: 17350563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotech acquisitions by big pharma: why and what is next.
    Malik NN
    Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nature of outsourced preclinical research--the example of chemical synthesis.
    Festel GW
    Expert Opin Drug Discov; 2013 Sep; 8(9):1049-55. PubMed ID: 23725522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic alliances and market risk.
    Havenaar M; Hiscocks P
    Drug Discov Today; 2012 Aug; 17(15-16):824-7. PubMed ID: 22484547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca.
    Janero DR
    Expert Opin Drug Discov; 2012 Jun; 7(6):449-56. PubMed ID: 22540843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
    Graul AI; Revel L; Tell M; Rosa E; Cruces E
    Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
    Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
    Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicologic pathology in a multicultural world--India.
    Schultze AE; Reddy VR; Donnelly KB; Berridge BR
    Toxicol Pathol; 2011 Oct; 39(6):1003-9. PubMed ID: 21859882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.